semaglutide cardiovascular outcomes news 2025 october currently not cost-effective for heart patients without diabetes, study finds Semaglutide Effects on Cardiovascular Outcomes

doi: 10.1002/mnfr.202200174 138 SmithBJHatterBWashburnKGraef-DownardJOjoBAEl-RassiGDet al

Results: What Adults Over 50 Can Realistically Expect Clinical trial data on GLP-1 medications generally skews toward younger to middle-aged adult populations, but real-world evidence and subgroup analyses suggest that adults over 50 achieve meaningful weight loss on these medications, though often at a somewhat slower pace than younger patients

A small proportion of patients (generally those with larger tumours) will need to continue with dopamine agonist therapy during pregnancy

Guarda la pluma con el capuchn puesto para proteger el producto de la luz